Seeking Alpha

Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but...

Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but were upstaged at a heart conference by the outcome of a Phase I trial of a rival treatment from Amgen (AMGN +1.5%), which was better. Still, both drugs have a long way to go before they'll be able to enter a market that could be worth $20B/year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)